NT5E and cancer: Different combination strategies of CD73 pharmacological inhibition with A2BR antagonist, chemotherapy and radiotherapy, anti-PD1/PD-L1 therapy, and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) improve cancer therapies[152]; Durvalumab (monoclonal antibody anti-PD-L1) and oleclumab (anti-CD73 monoclonal antibody) are being tested in NCT04668300 trial; this study includes osteosarcoma patients.